(Q38521011)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26054909%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

review article

1 reference

title

Advances in targeted therapies for hepatocellular carcinoma in the genomic era (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26054909%20AND%20SRC:MED&resulttype=core&format=json

Erratum: Advances in targeted therapies for hepatocellular carcinoma in the genomic era

16 February 2020

main subject

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

corrigendum / erratum

1 reference

10.1038/NRCLINONC.2015.121

DOI

12 July 2019

http://api.crossref.org/works?select=update-to&filter=doi:10.1038/NRCLINONC.2015.121

author

Josep M. Llovet

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26054909%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Augusto Villanueva

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26054909%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

Anja Lachenmayer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26054909%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Richard S Finn

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26054909%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

language of work or name

English

0 references

publication date

9 June 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26054909%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

16 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26054909%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26054909%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

408-424

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26054909%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26054909%20AND%20SRC:MED&resulttype=core&format=json

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

16 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

AACR Cancer Progress Report 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Molecular classification and novel targets in hepatocellular carcinoma: recent advancements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Gene signatures in the management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

MicroRNA expression, survival, and response to interferon in liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Cancer genes and the pathways they control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Shifting paradigms: the seeds of oncogene addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Targeted therapies for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Trans-ancestry mutational landscape of hepatocellular carcinoma genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Hepatocellular carcinoma pathogenesis: from genes to environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Genomics and signaling pathways in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

A critical role for notch signaling in the formation of cholangiocellular carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Notch signaling controls liver development by regulating biliary differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

SWI/SNF nucleosome remodellers and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

The preclinical development of regorafenib for the treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Pivotal role of mTOR signaling in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Targeting the HGF/c-MET pathway in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

HCC and angiogenesis: possible targets and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

VEGF signaling in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Design and endpoints of clinical trials in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Resection and liver transplantation for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

New designs for the selection of treatments to be tested in randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

TGF-β: duality of function between tumor prevention and carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Fibroblast growth factor signaling in liver carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Pancreatic Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Clinical trials in hepatocellular carcinoma: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeuti

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

MicroRNAs and other non-coding RNAs as targets for anticancer drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

A functional screening identifies five microRNAs controlling glypican-3: role of miR-1271 down-regulation in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Intratumor heterogeneity in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Liquid biopsy: monitoring cancer-genetics in the blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

A Phase I/II Trial Testing Immunization of Hepatocellular Carcinoma Patients with Dendritic Cells Pulsed with Four -Fetoprotein Peptides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Abstract A20: MK-3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): Preliminary safety and clinical activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

How to obtain the P value from a confidence interval

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.103

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26054909

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26054909